Sabrina Angelini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3165870/publications.pdf

Version: 2024-02-01

86 papers

4,542 citations

30 h-index 65 g-index

87 all docs

87 docs citations

87 times ranked

6868 citing authors

#	Article	IF	CITATIONS
1	Can <scp>miRNAs</scp> be useful biomarkers in improving prognostic stratification in endometrial cancer patients? An update review. International Journal of Cancer, 2022, 150, 1077-1090.	5.1	16
2	Relevance of ARID1A Mutations in Endometrial Carcinomas. Diagnostics, 2022, 12, 592.	2.6	6
3	Analysis of microbiome in gastrointestinal stromal tumors: Looking for different players in tumorigenesis and novel therapeutic options. Cancer Science, 2022, 113, 2590-2599.	3.9	4
4	ARID1A and CTNNB1 \hat{l}^2 -Catenin Molecular Status Affects the Clinicopathologic Features and Prognosis of Endometrial Carcinoma: Implications for an Improved Surrogate Molecular Classification. Cancers, 2021, 13, 950.	3.7	31
5	miRNA landscape in primary tumors and matched metastases in gastrointestinal stromal tumors. Epigenomics, 2021, 13, 369-377.	2.1	2
6	GH and IGF System: The Regulatory Role of miRNAs and IncRNAs in Cancer. Frontiers in Endocrinology, 2021, 12, 701246.	3.5	9
7	Role of Circulating miRNAs in Therapeutic Response in Epithelial Ovarian Cancer: A Systematic Revision. Biomedicines, 2021, 9, 1316.	3.2	3
8	Guidelines for the use and interpretation of assays for monitoring autophagy (4th) Tj ETQq0 0 0 rgBT /Overlock	10 Jf 50 4	62 Td (edition
9	Identification of miR-499a-5p as a Potential Novel Biomarker for Risk Stratification in Endometrial Cancer. Frontiers in Oncology, 2021, 11 , 757678 .	2.8	9
10	The "Elderly―Lesson in a "Stressful―Life: Italian Holistic Approach to Increase COVID-19 Prevention and Awareness. Frontiers in Endocrinology, 2020, 11, 579401.	3.5	6
11	Editorial: Liquid Biopsy as a Tool for Precision Oncology: New Challenges to Assess Clinical Response. Frontiers in Pharmacology, 2020, 11, 598261.	3.5	O
12	Gene duplication, rather than epigenetic changes, drives FGF4 overexpression in KIT/PDGFRA/SDH/RAS-P WT GIST. Scientific Reports, 2020, 10, 19829.	3.3	10
13	Gastric Adenocarcinomas and Signet-Ring Cell Carcinoma: Unraveling Gastric Cancer Complexity through Microbiome Analysis—Deepening Heterogeneity for a Personalized Therapy. International Journal of Molecular Sciences, 2020, 21, 9735.	4.1	25
14	Gene Expression Profiling of PDGFRA Mutant GIST Reveals Immune Signatures as a Specific Fingerprint of D842V Exon 18 Mutation. Frontiers in Immunology, 2020, 11, 851.	4.8	10
15	Pharmacogenetics in the treatment of gastrointestinal stromal tumors – an updated review. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 797-808.	3.3	2
16	<p>Mechanisms of resistance to a PI3K inhibitor in gastrointestinal stromal tumors: an omic approach to identify novel druggable targets</p> . Cancer Management and Research, 2019, Volume 11, 6229-6244.	1.9	2
17	Prognostic Role of miR-221 and miR-222 Expression in Cancer Patients: A Systematic Review and Meta-Analysis. Cancers, 2019, 11, 970.	3.7	43
18	Gastroblastoma in old age. Histopathology, 2019, 75, 778-782.	2.9	13

#	Article	IF	CITATIONS
19	The genetic legacy of the Yaghnobis: A witness of an ancient Eurasian ancestry in the historically reshuffled central Asian gene pool. American Journal of Physical Anthropology, 2019, 168, 717-728.	2.1	6
20	The rs17084733 variant in the <i>KIT</i> 3' UTR disrupts a miR-221/222 binding site in gastrointestinal stromal tumour: a sponge-like mechanism conferring disease susceptibility. Epigenetics, 2019, 14, 545-557.	2.7	10
21	Gain of FGF4 is a frequent event in KIT/PDGFRA/SDH/RASâ€P WT GIST. Genes Chromosomes and Cancer, 2019, 58, 636-642.	2.8	22
22	Clinical relevance of circulating molecules in cancer: focus on gastrointestinal stromal tumors. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591983190.	3.2	15
23	A meta-analysis of Italian and Estonian individuals shows an effect of common variants in HMGCR on blood apoB levels. Biomarkers in Medicine, 2019, 13, 931-940.	1.4	0
24	Preferential MGMT methylation could predispose a subset of KIT/PDGFRA-WT GISTs, including SDH-deficient ones, to respond to alkylating agents. Clinical Epigenetics, 2019, 11, 2.	4.1	15
25	An exploratory study by DMET array identifies a germline signature associated with imatinib response in gastrointestinal stromal tumor. Pharmacogenomics Journal, 2019, 19, 390-400.	2.0	20
26	Somatic pharmacogenomics of gastrointestinal stromal tumor., 2019, 2, 107-115.		1
27	The Sicilian Wolf: Genetic Identity of a Recently Extinct Insular Population. Zoological Science, 2019, 36, 189.	0.7	14
28	Old wild wolves: ancient DNA survey unveils population dynamics in Late Pleistocene and Holocene Italian remains. PeerJ, 2019, 7, e6424.	2.0	17
29	Absence of mutations in the human interferon alpha-2b gene in workers chronically exposed to ionising radiation. Arhiv Za Higijenu Rada I Toksikologiju, 2019, 70, 104-108.	0.7	0
30	Impact of SLC22A1 and CYP3A5 genotypes on imatinib response in chronic myeloid leukemia: A systematic review and meta-analysis. Pharmacological Research, 2018, 131, 244-254.	7.1	19
31	Relationship between Lipid Phenotypes, Overweight, Lipid Lowering Drug Response and KIF6 and HMG-CoA Genotypes in a Subset of the Brisighella Heart Study Population. International Journal of Molecular Sciences, 2018, 19, 49.	4.1	9
32	Current Knowledge on Endocrine Disrupting Chemicals (EDCs) from Animal Biology to Humans, from Pregnancy to Adulthood: Highlights from a National Italian Meeting. International Journal of Molecular Sciences, 2018, 19, 1647.	4.1	178
33	Gastrointestinal stromal tumors (GIST): Facing cell death between autophagy and apoptosis. Autophagy, 2017, 13, 452-463.	9.1	59
34	Genome-Wide Analysis Identifies MEN1 and MAX Mutations and a Neuroendocrine-Like Molecular Heterogeneity in Quadruple WT GIST. Molecular Cancer Research, 2017, 15, 553-562.	3.4	53
35	An exploratory association of polymorphisms in angiogenesis-related genes with susceptibility, clinical response and toxicity in gastrointestinal stromal tumors receiving sunitinib after imatinib failure. Angiogenesis, 2017, 20, 139-148.	7.2	10
36	Electrocardiogram Alterations Associated With Psychotropic Drug Use and CACNA1C Gene Variants in Three Independent Samples. Basic and Clinical Pharmacology and Toxicology, 2017, 120, 482-490.	2.5	10

3

#	Article	IF	CITATIONS
37	Trough concentration and <i>ABCG2</i> polymorphism are better to predict imatinib response in chronic myeloid leukemia: a meta-analysis. Pharmacogenomics, 2017, 18, 35-56.	1.3	34
38	Toward Precision Medicine: How Far Is the Goal?. International Journal of Molecular Sciences, 2016, 17, 245.	4.1	3
39	Pharmacogenetics of tyrosine kinase inhibitors in gastrointestinal stromal tumor and chronic myeloid leukemia. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 733-742.	3.3	24
40	Polymorphisms in DNA repair genes in gastrointestinal stromal tumours: susceptibility and correlation with tumour characteristics and clinical outcome. Tumor Biology, 2016, 37, 13413-13423.	1.8	19
41	Integrating miRNA and gene expression profiling analysis revealed regulatory networks in gastrointestinal stromal tumors. Epigenomics, 2016, 8, 1347-1366.	2.1	23
42	Application of the lymphocyte Cytokinesis-Block Micronucleus Assay to populations exposed to petroleum and its derivatives: Results from a systematic review and meta-analysis. Mutation Research - Reviews in Mutation Research, 2016, 770, 58-72.	5.5	13
43	Simultaneous Analysis of SEPT9 Promoter Methylation Status, Micronuclei Frequency, and Folate-Related Gene Polymorphisms: The Potential for a Novel Blood-Based Colorectal Cancer Biomarker. International Journal of Molecular Sciences, 2015, 16, 28486-28497.	4.1	21
44	Personalized Medicine in Gastrointestinal Stromal Tumor (GIST): Clinical Implications of the Somatic and Germline DNA Analysis. International Journal of Molecular Sciences, 2015, 16, 15592-15608.	4.1	32
45	Socio-Economic and Clinical Factors as Predictors of Disease Evolution and Acute Events in COPD Patients. PLoS ONE, 2015, 10, e0135116.	2.5	5
46	Key Genetic and Epigenetic Mechanisms in Chemical Carcinogenesis. Toxicological Sciences, 2015, 148, 2-13.	3.1	30
47	Polymorphisms in DNA repair genes: link with biomarkers of the CBMN cytome assay in hospital workers chronically exposed to low doses of ionising radiation / Polimorfizmi u genima za popravak DNA: poveznica s biomarkerima mikronukleus-testa u medicinskih radnika kroniAno izloženih niskim dozama ionizirajućeg zraÄenja. Arhiv Za Higijenu Rada I Toksikologiju, 2015, 66, 109-120.	0.7	15
48	Folate-related polymorphisms in gastrointestinal stromal tumours: susceptibility and correlation with tumour characteristics and clinical outcome. European Journal of Human Genetics, 2015, 23, 817-823.	2.8	17
49	miRNA profiling in gastrointestinal stromal tumors: implication as diagnostic and prognostic markers. Epigenomics, 2015, 7, 1033-1049.	2.1	27
50	Age- and glycemia-related miR-126-3p levels in plasma and endothelial cells. Aging, 2014, 6, 771-786.	3.1	105
51	The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia. Pharmacogenomics Journal, 2014, 14, 328-335.	2.0	45
52	Micronucleus frequency in human peripheral blood lymphocytes as a biomarker for the early detection of colorectal cancer risk. Mutagenesis, 2014, 29, 221-225.	2.6	31
53	Blood Biomarkers Linked to Oxidative Stress and Chronic Inflammation for Risk Assessment of Colorectal Neoplasia. Current Colorectal Cancer Reports, 2013, 9, 85-94.	0.5	3
54	Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with imatinib therapy. Pharmacological Research, 2013, 68, 1-6.	7.1	64

#	Article	IF	CITATIONS
55	Clinical relevance of pharmacogenetics in gastrointestinal stromal tumor treatment in the era of personalized therapy. Pharmacogenomics, 2013, 14, 941-956.	1.3	28
56	MED12 mutations in leiomyosarcoma and extrauterine leiomyoma. Modern Pathology, 2013, 26, 743-749.	5.5	102
57	Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy. Haematologica, 2013, 98, 193-200.	3.5	96
58	Environmental exposure to benzene, micronucleus formation and polymorphisms in DNA-repair genes: A pilot study. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2012, 743, 99-104.	1.7	25
59	Exposure to low environmental levels of benzene: Evaluation of micronucleus frequencies and S-phenylmercapturic acid excretion in relation to polymorphisms in genes encoding metabolic enzymes. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2011, 719, 7-13.	1.7	42
60	Association between the Germline MC1R Variants and Somatic BRAF/NRAS Mutations in Melanoma Tumors. Journal of Investigative Dermatology, 2010, 130, 2844-2848.	0.7	31
61	Specific Drug Transporter Genotypes Are Significantly Associated with Increased Rates of Major and Complete Molecular Responses In Newly Diagnosed Chronic Myeloid Leukemia Patients Treated with Imatinib $\hat{a} \in \text{``A TOPS Correlative Substudy. Blood, 2010, 116, 670-670.}$	1.4	0
62	Melanocortin receptor 1 variants and melanoma risk: A study of 2 European populations. International Journal of Cancer, 2009, 125, 1868-1875.	5.1	61
63	Modulation of Phase II Enzymes by Sulforaphane: Implications for Its Cardioprotective Potential. Journal of Agricultural and Food Chemistry, 2009, 57, 5615-5622.	5.2	104
64	Association Between Imatinib (IM) Transporters and Metabolizing Enzymes Genotype and Response in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients (Pts) Is Influenced by Ethnicity Blood, 2009, 114, 3283-3283.	1.4	0
65	Inherited susceptibility to bleomycin-induced micronuclei: Correlating polymorphisms in GSTT1, GSTM1 and DNA repair genes with mutagen sensitivity. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2008, 638, 90-97.	1.0	26
66	Micronuclei frequency induced by bleomycin in human peripheral lymphocytes: Correlating BLHX polymorphism with mutagen sensitivity. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2008, 639, 20-26.	1.0	12
67	Role of quercetin in modulating rat cardiomyocyte gene expression profile. American Journal of Physiology - Heart and Circulatory Physiology, 2008, 294, H1233-H1243.	3.2	39
68	Multidrug Resistance Gene (MDR1) Polymorphisms May Serve as Predictors of Resistance to Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients Blood, 2007, 110, 1946-1946.	1.4	0
69	Mutations in the BRAF and N-ras genes in childhood acute lymphoblastic leukaemia. Leukemia, 2005, 19, 310-312.	7.2	45
70	BRAF and NRAS Mutations Are Frequent in Nodular Melanoma but Are not Associated with Tumor Cell Proliferation or Patient Survival. Journal of Investigative Dermatology, 2005, 125, 312-317.	0.7	109
71	Micronuclei in humans induced by exposure to low level of ionizing radiation: influence of polymorphisms in DNA repair genes. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2005, 570, 105-117.	1.0	93
72	Low frequency of BRAF and CDKN2 Amutations in endometrial cancer. International Journal of Cancer, 2005, 115, 930-934.	5.1	46

#	Article	IF	CITATIONS
73	Effects of environmental benzene: Micronucleus frequencies and haematological values in traffic police working in an urban area. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2005, 583, 1-11.	1.7	59
74	Spectrum of chromosomal aberrations in peripheral lymphocytes of hospital workers occupationally exposed to low doses of ionizing radiation. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2004, 547, 91-99.	1.0	61
75	BRAF Mutations Are Common Somatic Events in Melanocytic NevillTables 2 and 3 can be found at http://www.blackwellpublishing.com/products/journals/suppmat/jid/jid22225/jid22225sm.htm. Journal of Investigative Dermatology, 2004, 122, 342-348.	0.7	206
76	A molecular epidemiological approach to health risk assessment of urban air pollution. Toxicology Letters, 2004, 149, 261-267.	0.8	13
77	Single nucleotide polymorphisms in breast cancer. Oncology Reports, 2004, 11, 917.	2.6	63
78	Single nucleotide polymorphisms in breast cancer. Oncology Reports, 2004, 11, 917-22.	2.6	114
79	Influence of commonXPDandXRCC1variant alleles onp53mutations in lung tumors. Environmental and Molecular Mutagenesis, 2003, 41, 37-42.	2.2	35
80	Activating BRAF and N-Ras mutations in sporadic primary melanomas: an inverse association with allelic loss on chromosome 9. Oncogene, 2003, 22, 9217-9224.	5.9	88
81	Simultaneous detection of the exon 10 polymorphism and a novel intronic single base insertion polymorphism in the XPD gene using single strand conformation polymorphism. Mutagenesis, 2003, 18, 207-209.	2.6	6
82	BRAF mutations in metastatic melanoma: a possible association with clinical outcome. Clinical Cancer Research, 2003, 9, 3362-8.	7.0	156
83	The XPD variant alleles are associated with increased aromatic DNA adduct level and lung cancer risk. Carcinogenesis, 2002, 23, 599-603.	2.8	207
84	Micronuclei frequencies in hospital workers occupationally exposed to low levels of ionizing radiation: influence of smoking status and other factors. Mutagenesis, 2002, 17, 405-409.	2.6	78
85	The Influence of Individual Genome Sensitivity in DNA Damage Repair Assessment in Chronic Professional Exposure to Low Doses of Ionizing Radiation. , 0, , .		6
86	Emerging Role of MicroRNAs in the Therapeutic Response in Cervical Cancer: A Systematic Review. Frontiers in Oncology, 0, 12, .	2.8	1